Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ACCD

Here's Why Accolade Shares Are Trading Higher Today

Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade, Inc (NASDAQ:ACCD) with a price target of $12. Following a problematic 4QF22, he noted that Accolade bounced back nicely in 1QF23 as the company beat management's initial outlook for FY23 revenue and adjusted EBITDA. While early in the selling season, ACCD won more new business in 1QF23 than…

Benzinga · Jul 1, 2022

Accolade Shares Slip After Q1 Results, Guides Q2 Revenue Below Consensus

Accolade Inc (NASDAQ:ACCD) reported first-quarter revenue growth of 44% year-over-year to $85.5 million, beating the consensus of $81.97 million. EPS was $(4.92), compared to $(0.84) in 1Q22. Adjusted gross profit increased by 63% Y/Y to $39 million, and margin expanded by 545 bps to 45.6%. Adjusted EBITDA loss widened to $(15.4) million…

Benzinga · Jun 30, 2022

Jimmy Carter and disability rights

In 1977, people with disabilities occupied federal buildings across America. It was the beginning of something big

Salon · May 1, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Are Accolade Shares Down Over 40% Today

Accolade Inc (NASDAQ:ACCD) shares plunged almost 50% after disappointing Q4 FY22 earnings and FY23 guidance. Q4 FY22 revenue increased 58% Y/Y to $93.8 million, beating the consensus of $91.57 million. The company reported a wider net loss of $(34.56) million compared to $(4.73) million a year ago. EPS loss came at $(0.51)…

Benzinga · Apr 29, 2022

What 5 Analyst Ratings Have To Say About Accolade

Accolade (NASDAQ:ACCD) has observed the following analyst ratings within the last quarter:

Benzinga · Mar 3, 2022

Analyst Ratings For Accolade

Over the past 3 months, 5 analysts have published their opinion on Accolade (NASDAQ:ACCD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · Feb 11, 2022

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.